Seminars in Oncology
Volume 37, Issue 3 , Pages 202-215 , June 2010

Principles of Cancer Screening: Lessons From History and Study Design Issues

  • Jennifer M. Croswell

      Affiliations

    • Office of Medical Applications of Research, National Institutes of Health, Bethesda, MD
    • Corresponding Author InformationAddress correspondence to Jennifer M. Croswell, MD, MPH, Acting Director, Office of Medical Applications of Research, National Institutes of Health, 6100 Executive Blvd., Suite 2B-03, Bethesda, MD 20892
    • ,
  • David F. Ransohoff

      Affiliations

    • Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
    • ,
  • Barnett S. Kramer

      Affiliations

    • Office of Disease Prevention, National Institutes of Health, Bethesda, MD

References 

  1. Han PK. Historical changes in the objectives of the periodic health examination. Ann Intern Med. 1997;127:910–917
  2. Boulware LE, Barnes GJ, Wilson RF, et al. Value of the periodic health evaluation (Evidence report/technology assessment no. 136). (Prepared by The Johns Hopkins University Evidence-based Practice Center under Contract No. 290-02-0018). AHRQ Publication No. 06-E011 Rockville, MD: Agency for Healthcare Research and Quality; April 2006;
  3. Dobell H. Lectures on the germs and vestiges of disease, and on the prevention of the invasion and fatality of disease by periodical examinations. London: Churchill; 1861;
  4. Gould GM. A system of personal biologic examinations the condition of adequate medical and scientific conduct of life. JAMA. 1900;284:134–138
  5. Childe CP. The control of a scourge, or how cancer is curable. New York: Dutton; 1907;
  6. Emerson H. Periodic medical examinations of apparently healthy persons. JAMA. 1923;80:1376–1381
  7. Lerner BH. The breast cancer wars. New York: Oxford University Press; 2001;
  8. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968;whqlibdoc.who.int/php/WHO_PHP_34.pdfOctober 15, 2009
  9. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113:18–25
  10. Sadler L, Saftlas A, Wang W, et al. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA. 2004;291:2100–2106
  11. Kramer BS, Brawley OW. Cancer screening. Hematol Oncol Clin North Am. 2000;14:831–848
  12. Dales LG, Ramcharan S, Feldman R, et al. Multiphasic Health Checkup Evaluation Study. 3 (Outpatient clinic utilization, hospitalization, and mortality experience after seven years). Prev Med. 1973;2:221–235
  13. Friedman GD, Collen MF, Fireman BH. Multiphasic Health Checkup Evaluation: a 16-year follow-up. J Chronic Dis. 1986;39:453–463
  14. The South-East London Screening Study Group. A controlled trial of multiphasic screening in middle-age: results of the South-East London Screening Study. Int J Epidemiol. 1977;6:357–363
  15. Habbema JD, van Oortmarssen GJ, van Putten DJ, et al. Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the Health Insurance Plan of Greater New York study. J Natl Cancer Inst. 1986;77:317–320
  16. Andersson I, Aspegren K, Janzon L, et al. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. BMJ. 1988;297:943–948
  17. Tabár L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography (Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare). Lancet. 1985;1:829–832
  18. Muhm JR, Miller WE, Fontana RS, Sanderson DR, Uhlenhopp MA. Lung cancer detected during a screening program using four month chest radiographs. Radiology. 1983;148:609–615
  19. Stitik FP, Tockman MS. Radiographic screening in the early detection of lung cancer. Radiol Clin North Am. 1978;16:347–366
  20. Melamed MR, Flehinger BJ, Zaman MB, et al. Screening for early lung cancer (Results of the Memorial Sloan-Kettering study in New York). Chest. 1984;86:44–53
  21. Marcus PM, Bergstrahl EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: Impact of extended follow-up. J Natl Cancer Inst. 2000;92:1308–1316
  22. Harris RP, Helfand M, Woolf SH, et al. Current methods of the U.S. Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21–35
  23. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248:1465–1477
  24. Church TR, Ederer F, Mandel JS, et al. Estimating the duration of ongoing prevention trials. Am J Epidemiol. 1993;137:797–810
  25. Final report on the aspirin component of the ongoing Physicians' Health Study (Steering Committee of the Physicians' Health Study Research Group). N Engl J Med. 1989;321:129–135
  26. Hara M, Sasaki S, Sobue T, Yamamoto S, Tsugane S. Comparison of cause-specific mortality between respondents and nonrespondents in a population-based prospective study: ten-year follow-up of JPHC Study Cohort I (Japan Public Health Center). J Clin Epidemiol. 2002;55:150–156
  27. Pinsky PF, Miller A, Kramer BS, et al. Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Epidemiol. 2007;165:874–881
  28. Shen Y, Yang Y, Inoue LY, et al. Role of detection method in predicting breast cancer survival: Analysis of randomized screening trials. J Natl Cancer Inst. 2005;97:1195–1203
  29. Krzyzanowska M, Tannock I. Should screen-detected breast cancers be managed differently?. J Natl Cancer Inst. 2005;97:1170–1171
  30. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101:1325–1329
  31. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328
  32. Yamamoto K, Hayashi Y, Hanada R, et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. J Clin Oncol. 1995;13:2033–2038
  33. Woods WG, Tuchman M, Robison LL, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet. 1996;348:1682–1687
  34. Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002;346:1041–1046
  35. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346:1047–1053
  36. Yamamoto K, Ohta S, Ito E, et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol. 2002;5:1209–1214
  37. Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol. 2000;18:477–486
  38. Brodeur GM, Look AT, Shimada H, et al. Biological aspects of neuroblastomas identified by mass screening in Quebec. Med Pediatr Oncol. 2001;36:157–159
  39. Kitanaka C, Kato K, Ijiri R, et al. Increased Ras expression and caspase-independent neuroblastoma cell death: Possible mechanism of spontaneous neuroblastoma regression. J Natl Cancer Inst. 2002;94:358–368
  40. Katanoda K, Hayashi K, Yamamoto K, Sobue T. Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan. J Epidemiol. 2009;19:266–270
  41. Wolpaw DR. Early detection in lung cancer (Case finding and screening). Med Clin North Am. 1996;80:63–82
  42. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews. 2009;4:CD001877
  43. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302:1685–1692
  44. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998;338:1089–1096
  45. Croswell JM, Kramer BS, Kreimer AR, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med. 2009;7:212–222
  46. McNaughton-Collins M, Fowler FJ, Caubet JF, et al. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med. 2004;117:719–725
  47. Fowler FJ, Barry MJ, Walker-Corkery B, et al. The impact of a suspicious prostate biopsy on patients' psychological, socio-behavioral, and medical care outcomes. J Gen Intern Med. 2006;21:715–721
  48. Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. Am J Respir Crit Care Med. 2008;178:956–961
  49. Lafata JE, Simpkins J, Lamerato L, et al. The economic impact of false-positive cancer screens. Cancer Epidemiol Biomarkers Prev. 2004;13:2126–2132
  50. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med. 1978;299:741–744
  51. de Boer AG, Taskila T, Ojajärvi A, van Dijk FJ, Verbeek JH. Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA. 2009;301:753–762
  52. Main DS, Nowels CT, Cavender TA, Etschmaier M, Steiner JF. A qualitative study of work and work return in cancer survivors. Psychooncology. 2005;14:992–1004
  53. Nachreiner NM, Dagher RK, McGovern PM, Baker BA, Alexander BH, Gerberich SG. Successful return to work for cancer survivors. AAOHN J. 2007;55:290–295
  54. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcomes among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261
  55. Potosky AL, David WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96:1358–1367
  56. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–1137
  57. Catalona WJ. Screening for prostate cancer: enthusiasm. Urology. 1993;42:113–115
  58. Lung Cancer Alliance. LCA Position on Lung Cancer Screening. http://www.lungcanceralliance.org/eirc/screen/screening_positions.htmlOctober 26, 2009;November 1, 2009
  59. McNaughton Collins M, Barry MJ. Controversies in prostate cancer screening: Analogies to the early lung cancer screening debate. JAMA. 1996;276:196–199
  60. Barry MJ. Screening for prostate cancer—the controversy that refuses to die. N Engl J Med. 2009;360:1351–1354
  61. Kawachi MH, Babaian RJ, Bahnson RR, et al. National Comprehensive Cancer Network Practice Guidelines in Oncology, v.2.2010: Prostate Cancer Early Detection. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#siteAugust 7, 2009;October 15, 2009
  62. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89
  63. Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computer tomography scanner. Lancet. 1998;351:1242–1245
  64. Sone S, Li F, Yang ZG, et al. Characteristics of small lung cancers invisible on conventional chest radiography and detected by population based screening using spiral CT. Br J Radiol. 2000;73:137–145
  65. Sone S, Li F, Yang ZG, et al. Results of 3-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer. 2001;84:25–32
  66. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer (Veterans Affairs Cooperative Study Group 380). N Engl J Med. 2000;343:162–168
  67. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med. 2000;343:169–174
  68. Podolsky DK. Going the distance—the case for true colorectal cancer screening. N Engl J Med. 2000;343:207–208
  69. Grady D. More extensive test needed for colon cancer, studies say. The New York Times; July 20, 2000;Section A, p.1, column 5
  70. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. (Preventive Services Task Force). Ann Intern Med. 2002;137:96–104
  71. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150:1–8
  72. Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst. 2010;102:89–95
  73. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guidelines from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–160

PII: S0093-7754(10)00071-0

doi: 10.1053/j.seminoncol.2010.05.006

Seminars in Oncology
Volume 37, Issue 3 , Pages 202-215 , June 2010

Article Tools

* Image Usage & Resolution